A drug-eluting stent
By designing multiple open-loop drug stents, using wire connections and corrugated structures, combining the use of taurine and rapamycin, the problem of restenosis caused by drug stents in the prior art was solved, and the problem of vascular restenosis was achieved. Effective treatment and vascular protection of ruptured intracranial aneurysms.
Patent Information
- Application Number
- CN202111043470.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-09-07
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-09-07
AI Technical Summary
Existing drug stents are prone to intrastent restenosis in the treatment of intracranial aneurysms, and there is a lack of treatment options for unruptured intracranial aneurysms.
Design a drug stent with multiple open ring structures, connected by wire, the body of the stent is a corrugated structure surrounded by wire, the groove is filled with taurine and/or rapamycin, and is encapsulated and arranged using a degradable membrane. Micropores, grooves are spaced apart to control drug release, and hollow structures are provided at the contact point between the stent and the blood vessel wall to provide radial support.
It effectively reduces the risk of restenosis in the stent, improves the treatment effect of intracranial aneurysms, reduces the risk of rupture, and protects intracranial blood vessels.
Smart Images

Figure CN113679516B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug stents, in particular to a drug stent. Background Art
[0002] Unruptured intracranial aneurysms are likened to "time bombs" buried in the brain. Rupture will cause cerebral hemorrhage, which can lead to 30% to 40% of patients dying on the spot. Among the surviving patients, some will still be severely disabled after treatment, and some will recover well but will not be able to fully perform their original work and normal life.
[0003] With the continuous improvement of surgical methods and the emergence of new materials and technologies, some difficult intracranial aneurysms can be better treated. There are two treatment methods: craniotomy to clip aneurysms and interventional therapy, namely endovascular embolization technology. However, craniotomy is risky and endovascular embolization technology can cause postoperative complications.
[0004] Studies have reported that drug-eluting stents can be used to treat intracranial aneurysms with good results, but current drug-eluting stents are prone to causing restenosis of the blood vessels within the stent, and there is currently no research on drug-eluting stents for the treatment of unruptured intracranial aneurysms. Summary of the invention
[0005] 1. Technical issues to be resolved
[0006] In view of the above-mentioned shortcomings and deficiencies of the prior art, the present invention provides a drug-eluting stent, which can reduce restenosis of blood vessels in the stent and protect intracranial blood vessels.
[0007] (II) Technical solution
[0008] In order to achieve the above object, the main technical solutions adopted by the present invention include:
[0009] The present invention provides a drug stent, which has an expanded state and a contracted state. The inner diameter of the drug stent in the expanded state is larger than the inner diameter in the contracted state. The drug stent comprises: a stent body, which is an open-loop structure; a plurality of stent bodies are arranged along the axial direction of the drug stent, and the plurality of stent bodies are connected by metal wires; the stent body comprises a plurality of coaxially arranged annular stent bodies, and a connector for connecting two adjacent stent bodies; a plurality of grooves are arranged along the circumference of the stent body on one side of the stent body in contact with the blood vessel wall, and the grooves are filled with at least one drug.
[0010] Furthermore, the drug is taurine and / or rapamycin.
[0011] Furthermore, the drug is encapsulated in the groove through a degradable film.
[0012] Furthermore, a plurality of micropores are arranged on the degradable membrane.
[0013] Furthermore, the groove is filled with two drugs, and the two drugs are separated by a degradable film.
[0014] Furthermore, the cross section of the groove is V-shaped.
[0015] Furthermore, the support body is a corrugated structure surrounded by metal wires, which is used to provide radial supporting force.
[0016] Furthermore, the crests and troughs on the adjacent sides of the two bracket bodies are arranged opposite to each other, or the crests and crests are arranged opposite to each other, and the connector is used to connect the crests and troughs on the adjacent sides of the two bracket bodies, thereby forming a hollow.
[0017] Further, the stent body further comprises at least one radiopaque tab mounted on at least one of the front open end and the rear open end, the tab being used to improve radiopaqueness of the stent.
[0018] Furthermore, the stent body is made of metal wire.
[0019] (III) Beneficial effects
[0020] The beneficial effects of the present invention are as follows: the present invention provides a drug-eluting stent, which adopts a plurality of stent bodies with open-loop structures, and the plurality of stent bodies are connected by metal wires, which can effectively support the blood vessel wall and reduce restenosis of the blood vessel in the stent; at least one drug is filled in the groove of the stent body, and the lesions in the blood vessel can be effectively treated according to different purposes, and the risk of rupture of intracranial aneurysms can be effectively reduced, so as to achieve the effect of treating unruptured intracranial aneurysms and protect the intracranial blood vessels. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1 The figure is a schematic diagram of the structure of a drug-eluting stent according to the present invention.
[0022] Figure 2 For the present invention Figure 1 Schematic diagram of the enlarged structure at point A in the middle.
[0023] Figure 3 For the present invention Figure 2 Middle BB section view.
[0024] [Description of Reference Numerals]
[0025] 100. Support body;
[0026] 110, support body; 111, groove; 112, wave crest; 113, wave trough;
[0027] 120, connector;
[0028] 130. Degradable film;
[0029] 140, hollow;
[0030] 150, front open end;
[0031] 160, rear open end;
[0032] 170. Radiopaque tabs. DETAILED DESCRIPTION
[0033] In order to better understand the above technical solution, exemplary embodiments of the present invention will be described in more detail below with reference to the accompanying drawings. Although exemplary embodiments of the present invention are shown in the accompanying drawings, it should be understood that the present invention can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided to enable a clearer and more thorough understanding of the present invention and to fully convey the scope of the present invention to those skilled in the art.
[0034] Example: Refer to Figure 1 The present invention provides a drug stent. The drug stent has an expanded state and a contracted state. The inner diameter of the drug stent in the expanded state is greater than the inner diameter in the contracted state, and the length of the drug stent in the expanded state is less than the length in the contracted state. The drug stent includes a plurality of stent bodies 100 made of metal wires, each of which has a front open end 150 and a rear open end 160, and the two stent bodies 100 are connected by metal wires. The stent body 100 is an open-loop structure. Designing the stent body 100 as an uninterrupted open-loop structure can increase the flexibility of the pre-installed stent during the implantation process, and the stent will have better wall adhesion after release, so that the drug can be better released to the lesion.
[0035] The stent body 100 includes a plurality of coaxially arranged annular stent bodies 110 and a connecting body 120 for connecting two adjacent stent bodies 110 .
[0036] Among them, the stent body 110 is a corrugated structure surrounded by metal wires, which is used to provide radial support force to the stent body 100. The connector 120 is also made of metal wires. In the present invention, the metal wires of the stent body 110 and the connector 120 can be nickel-titanium alloys, and can also be metal tantalum, cobalt-chromium alloys or absorbable metal materials. The absorbable materials can be materials such as magnesium alloys or zinc-based alloys. The metal wire of this embodiment is selected from nickel-titanium alloy, mainly because nickel-titanium alloy is a memory alloy, has the advantages of self-expansion, is easy to compress, and has better wall adhesion after expansion, has good corrosion resistance and fatigue resistance, strong radial support force, small shortening rate of the stent after expansion, and good visibility under perspective. The overall flexibility of the nickel-titanium alloy stent is good, and compared with other materials, it is easier to restore its shape after extrusion.
[0037] The connector 120 is designed to be a curved U-shaped structure, which can facilitate the compression and expansion of the stent.
[0038] In the middle part of the stent body 100, the crests 112 and crests 112 of the adjacent sides of the two stent bodies 110 are arranged opposite to each other, and the troughs 113 and troughs 113 are arranged opposite to each other. Since the diameters of the two ends of the stent body 100 when unfolded are larger than the diameter of the middle part, the number of corrugations of the stent body 110 at the two ends of the stent body 100 is greater than the number of corrugations of the stent body 110 in the middle part, resulting in that the crests 112 or troughs 113 of the stent body 110 at the two ends may be opposite to the troughs 113 or crests 112 of the adjacent stent body 110. The connector 120 is used to connect the crests 112 and crests 112 or the troughs 113 and troughs 113 of the adjacent sides of the two stent bodies 110, thereby forming a hollow 140.
[0039] In this embodiment, the stent body 110 and the stent body 110 on the adjacent side thereof are connected by a connector 120 to connect the crest 112 and the trough 113; there is a crest 112 between the two connectors 120 on one side of the crest 112 of the stent body 110. The above structure can improve the flexibility of the stent and prevent the radial supporting force of the stent from being too large or too small, thereby supporting the blood vessel wall and causing no damage to the blood vessel wall after surgery.
[0040] In this embodiment, the connector 120 is a metal wire with a U-shaped structure. Designing the connector 120 with a U-shaped structure can increase the radial support force of the stent; and compared with the connector 120 with a linear structure, the connector 120 with a U-shaped structure can reduce the shortening rate of the stent.
[0041] The drug stent of the present invention uses a connector 120 to connect the crests 112 and troughs 113 on adjacent sides of two stent bodies 110 to form a hollow 140, thereby improving the radial support force and flexibility of the stent.
[0042] Reference Figure 2 and Figure 3 , a plurality of grooves 111 are provided along the circumference of the stent body 110 on the side where the stent body 110 contacts the blood vessel wall, and at least one drug is filled in the grooves 111; the drug is taurine and / or rapamycin. Specifically, the grooves 111 are arranged on the stent body 110 between the crest 112 and the trough 113, and the opening of the grooves 111 faces one side of the blood vessel wall, so that the stent body 110 can better transport the drug, directly apply the drug to the lesion, and effectively treat and protect the blood vessel. The cross section of the groove 111 can be V-shaped, which is beneficial to the release of the drug on the one hand and convenient for processing on the other hand. Of course, the present invention is not limited to the above structure, and the cross section of the groove 111 can also be rectangular, trapezoidal, etc.
[0043] Rapamycin can be used to treat vascular stenosis, while supplementing taurine can normalize serum taurine levels and significantly reduce the incidence and rupture risk of intracranial aneurysms. In addition, taurine can also inhibit cerebrovascular inflammatory response, extracellular matrix remodeling, MMP-9 activity, and apoptosis of cerebral vascular smooth muscle cells. The present invention uses rapamycin and / or taurine as drugs in drug stents, which can effectively reduce the rupture rate of unruptured intracranial aneurysms and protect blood vessels.
[0044] The drug is encapsulated in the groove 111 by the degradable film 130, so as to prevent the drug from falling out of the groove 111 and affecting the treatment effect during the process of delivering the drug stent into the blood vessel. In addition, the degradable film 130 is provided with a plurality of micropores, so that the drug can be released from the micropores first after the drug stent is delivered into the blood vessel. As the degradable film 130 degrades, more drugs can be released into the blood vessel, so as to achieve a better treatment effect.
[0045] Specifically, when a drug is filled in the groove 111, taurine and rapamycin can be filled alternately in multiple grooves 111 in the circumferential direction of the stent body 110. For example, if taurine is filled in one groove 111, then rapamycin is filled in another adjacent groove 111, and the degradation time of the degradable film 130 above the groove 111 filled with rapamycin is shorter than the degradation time of the degradable film 130 above the groove 111 filled with taurine, so that rapamycin can be released first to treat vascular stenosis, and taurine can be released later to protect blood vessels. When the drug stent is delivered into the blood vessel, the groove 111 filled with rapamycin can correspond to the lesion, and the adjacent groove 111 filled with taurine can correspond to the edge of the lesion, which can better treat vascular stenosis and protect blood vessels. Of course, the present invention is not limited to the above structure. Taurine can be filled in the lower layer of the same groove 111, and rapamycin can be filled in the upper layer. Taurine and rapamycin are separated by a degradable film 130 to avoid mixing the two components and affecting the treatment effect. The degradation time of the degradable film 130 between taurine and rapamycin is greater than the degradation time of the degradable film 130 encapsulating rapamycin, so that rapamycin can be released first and taurine can be released later.
[0046] On the basis of the above-mentioned embodiment, the stent body 100 of the present invention further includes at least one radiopaque tab 170 installed on at least one of the front open end 150 and the rear open end 160, and the tab is used to improve the radiopaqueness of the stent body 100, so that the stent body 100 has good visualization. In this embodiment, three radiopaque tabs 170 are respectively arranged on the front open end 150 and the rear open end 160 of the stent body 100.
[0047] In the present invention, unless otherwise clearly specified and limited, the terms "installed", "connected", "connected", "fixed" and the like should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection or an indirect connection through an intermediate medium; it can be the internal connection of two elements or the interaction relationship between two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances.
[0048] In the present invention, unless otherwise clearly specified and limited, when a first feature is “on” or “below” a second feature, it may be that the first and second features are in direct contact, or that the first and second features are in indirect contact through an intermediate medium. Moreover, when a first feature is “above”, “above” or “above” a second feature, it may be that the first feature is directly above or obliquely above the second feature, or it may simply mean that the first feature is higher in level than the second feature. When a first feature is “below”, “below” or “below” a second feature, it may be that the first feature is directly below or obliquely below the second feature, or it may simply mean that the first feature is lower in level than the second feature.
[0049] In the description of this specification, the description of the terms "one embodiment", "some embodiments", "embodiment", "example", "specific example" or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, unless they are contradictory.
[0050] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may alter, modify, replace and modify the above embodiments within the scope of the present invention.
Claims
1. A drug stent having an expanded state and a contracted state, wherein the inner diameter of the drug stent in the expanded state is greater than the inner diameter of the drug stent in the contracted state, characterized in that: include: A stent body (100), wherein the stent body (100) is an open-loop structure; A plurality of the stent bodies (100) are arranged along the axial direction of the drug stent, and the plurality of stent bodies (100) are connected by metal wires; The stent body (100) comprises a plurality of coaxially arranged annular stent bodies (110), and a connector (120) for connecting two adjacent stent bodies (110); A side of the stent body (110) in contact with the blood vessel wall is provided with a plurality of grooves (111) along the circumference of the stent body (110), the openings of the grooves (111) face one side of the blood vessel wall, and the grooves (111) are filled with at least one drug; The drug is encapsulated in the groove (111) via a degradable film (130); The degradable film (130) is provided with a plurality of micropores; One of the grooves (111) is filled with taurine, and another adjacent groove (111) is filled with rapamycin, and the degradation time of the degradable film (130) above the groove (111) filled with rapamycin is shorter than the degradation time of the degradable film (130) above the groove (111) filled with taurine; or, The lower layer of the same groove (111) is filled with taurine, and the upper layer is filled with rapamycin. Taurine and rapamycin are separated by the degradable film (130), and the degradation time of the degradable film (130) between taurine and rapamycin is greater than the degradation time of the degradable film (130) encapsulating rapamycin.
2. The drug stent according to claim 1, characterized in that: The cross section of the groove (111) is V-shaped.
3. The drug stent according to claim 1, characterized in that: The support body (110) is a corrugated structure formed by metal wires and is used to provide radial supporting force.
4. The drug stent according to claim 1, characterized in that: The wave crests (112) and the wave troughs (113) on the adjacent sides of the two support bodies (110) are arranged opposite to each other, or the wave crests (112) and the wave crests (112) are arranged opposite to each other, and the connecting body (120) is used to connect the wave crests (112) and the wave troughs (113) on the adjacent sides of the two support bodies (110), thereby forming a hollow (140).
5. The drug stent according to claim 1, characterized in that: The stent body (100) further comprises at least one radiopaque tab (170) mounted on at least one of the front open end (150) and the rear open end (160), the tab being used to improve the radiopaqueness of the stent.
6. The drug-eluting stent according to claim 1, characterized in that: The stent body (100) is made of metal wire.
Citation Information
Patent Citations
Dual drug stent
CN101874907A
Drug-loading intravascular stent and preparation method thereof
CN107496996A
Self-expanding stent suitable for intracranial venous sinus and delivery system thereof
CN112353535A
Drug stent
CN216221895U
Devices and methods for treatment of stenotic regions
US20040236414A1
